Figure 1: Impact Analysis on the Global IVD Market
Figure 2: Global IVD Market (by Product), $Million, 2020 vs. 2030
Figure 3: Global IVD Market (by Test Type), $Million, 2020 vs. 2030
Figure 4: Global IVD Market (by Application), $Million, 2020 vs. 2030
Figure 5: Global IVD Market (by End User), $Million, 2020 vs. 2030
Figure 6: Global IVD Market Snapshot (by Region)
Figure 2.1: Global IVD Market Segmentation
Figure 3.1: Global IVD Market Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Top-Down Approach (Segment-Wise Analysis)
Figure 3.4: Bottom-up Approach (Segment-Wise Analysis)
Figure 4.1: Global IVD Market, 2019-2030
Figure 5.1: Global IVD Market, Pre- vs. Post-COVID-19
Figure 6.1: Global IVD Market: Market Dynamics
Figure 7.1: Global IVD Market, (by Product), $Million, 2020 vs. 2030
Figure 7.2: IVD Instrument Market, $Million, 2019-2030
Figure 7.3: IVD Consumables Market, $Million, 2019-2030
Figure 7.4: IVD Kits Market, $Million, 2019-2030
Figure 7.5: IVD Reagents Market, $Million, 2019-2030
Figure 7.6: IVD Software Market, $Million, 2019-2030
Figure 8.1: Global IVD Market (by Test Type), $Million, 2020 vs. 2030
Figure 8.2: IVD Immunoassay Market, $Million, 2019-2030
Figure 8.3: IVD Clinical Chemistry Market, $Million, 2019-2030
Figure 8.4: IVD Whole Blood Glucose Monitoring Market, $Million, 2019-2030
Figure 8.5: IVD Molecular Diagnostics Market, $Million, 2019-2030
Figure 8.6: IVD Microbiology Market, $Million, 2019-2030
Figure 8.7: IVD Anatomic Pathology Market, $Million, 2019-2030
Figure 8.8: IVD Hematology Market, $Million, 2019-2030
Figure 8.9: IVD Coagulation Market, $Million, 2019-2030
Figure 8.10: IVD Critical Care Market, $Million, 2019-2030
Figure 8.11: IVD Urinalysis Market, $Million, 2019-2030
Figure 8.12: IVD Other Test Type Market, $Million, 2019-2030
Figure 9.1: Global IVD Market (by Application), $Million, 2020 vs. 2030
Figure 9.2: IVD Market for Diabetes, $Million, 2019-2030
Figure 9.3: IVD Market for Infectious Disease, $Million, 2019-2030
Figure 9.4: IVD Market for Oncology/Cancer, $Million, 2019-2030
Figure 9.5: IVD Market for Cardiology, $Million, 2019-2030
Figure 9.6: IVD Market for Nephrology, $Million, 2019-2030
Figure 9.7: IVD Market for Autoimmune Disease, $Million, 2019-2030
Figure 9.8: IVD Market for Drug Testing/Pharmacogenomics, $Million, 2019-2030
Figure 9.9: IVD Market for HIV/AIDS, $Million, 2019-2030
Figure 9.10: IVD Market for Women Health, $Million, 2019-2030
Figure 9.11: IVD Market for Other Applications, $Million, 2019-2030
Figure 10.1: Global IVD Market (by End User), $Million, 2020 vs. 2030
Figure 10.2: IVD Market for Hospitals, $Million, 2019-2030
Figure 10.3: IVD Market for Central Laboratories, $Million, 2019-2030
Figure 10.4: IVD Market for POC, $Million, 2019-2030
Figure 10.5: IVD Market for Clinics, $Million, 2019-2030
Figure 10.6: IVD Market for Academic Institutions, $Million, 2019-2030
Figure 10.7: IVD Market for Other End Users, $Million, 2019-2030
Figure 11.1: Global IVD Market, $Million, 2019-2030
Figure 11.2: North America: Market Dynamics
Figure 11.3: North America IVD Market, $Million, 2019-2030
Figure 11.4: North America IVD Market (by Country), $Million, 2020 vs. 2030
Figure 11.5: U.S. IVD Market, $Million, 2019-2030
Figure 11.6: Canada IVD Market, $Million, 2019-2030
Figure 11.7: Europe: Market Dynamics
Figure 11.8: Europe IVD Market, $Million, 2019-2030
Figure 11.9: Europe IVD Market (by Country), $Million, 2020 vs. 2030
Figure 11.10: Germany IVD Market, $Million, 2019-2030
Figure 11.11: U.K. IVD Market, $Million, 2019-2030
Figure 11.12: France IVD Market, $Million, 2019-2030
Figure 11.13: Italy IVD Market, $Million, 2019-2030
Figure 11.14: Spain IVD Market, $Million, 2019-2030
Figure 11.15: Netherlands IVD Market, $Million, 2019-2030
Figure 11.16: Rest-of-Europe IVD Market, $Million, 2019-2030
Figure 11.17: Asia-Pacific: Market Dynamics
Figure 11.18: Asia-Pacific IVD Market, $Million, 2019-2030
Figure 11.19: Europe IVD Market (by Country), $Million, 2020 vs. 2030
Figure 11.20: Japan IVD Market, $Million, 2019-2030
Figure 11.21: China IVD Market, $Million, 2019-2030
Figure 11.22: India IVD Market, $Million, 2019-2030
Figure 11.23: South Korea IVD Market, $Million, 2019-2030
Figure 11.24: Australia IVD Market, $Million, 2019-2030
Figure 11.25: Rest-of-APAC IVD Market, $Million, 2019-2030
Figure 11.26: Latin America: Market Dynamics
Figure 11.27: Latin America IVD Market, $Million, 2019-2030
Figure 11.28: Latin America IVD Market (by Country), $Million, 2020 vs. 2030
Figure 11.29: Brazil IVD Market, $Million, 2019-2030
Figure 11.30: Mexico IVD Market, $Million, 2019-2030
Figure 11.31: Rest-of-Latin America IVD Market, $Million, 2019-2030
Figure 11.32: Middle East: Market Dynamics
Figure 11.33: Middle East IVD Market, $Million, 2019-2030
Figure 11.34: Middle East IVD Market (by Country), $Million, 2020 vs. 2030
Figure 11.35: Saudi Arabia IVD Market, $Million, 2019-2030
Figure 11.36: Israel IVD Market, $Million, 2019-2030
Figure 11.37: Rest-of-Middle East IVD Market, $Million, 2019-2030
Figure 11.38: Rest of the World IVD Market, $Million, 2019-2030
Figure 13.1: Share of Key Developments and Strategies, January 2017-April 2020
Figure 13.2: Product Launches and Enhancements Share (by Company), January 2017-April 2020
Figure 13.3: Approvals Share (by Company), January 2017-April 2020
Figure 13.4: Synergistic Activities Share (by Company), January 2017-April 2020
Figure 13.5: Acquisition and Merger Share (by Company), January 2017-April 2020
Figure 13.6: Market Share Analysis for the Global IVD Market, 2019
Figure 13.7: Growth Share Matrix for Global IVD Market (by Company)
Figure 14.1: Agilent Technologies, Inc.: Key Product Portfolio
Figure 14.2: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 14.3: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 14.4: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 14.5: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 14.6: Agilent Technologies, Inc.: SWOT Analysis
Figure 14.7: F. Hoffmann-La Roche AG: Key Product Portfolio
Figure 14.8: F. Hoffmann-La Roche AG: Overall Financials, 2017-2019
Figure 14.9: F. Hoffmann-La Roche AG: Revenue (by Segment), $Million, 2017-2019
Figure 14.10: F. Hoffmann-La Roche AG: Revenue (by Region), 2017-2019
Figure 14.11: F. Hoffmann-La Roche AG: R&D Expenditure, 2017-2019
Figure 14.12: F. Hoffmann-La Roche AG: SWOT Analysis
Figure 14.13: Illumina, Inc.: Key Product Portfolio
Figure 14.14: Illumina, Inc.: Overall Financials, 2017-2019
Figure 14.15: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 14.16: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 14.17: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 14.18: Illumina, Inc.: SWOT Analysis
Figure 14.19: QIAGEN N.V.: Key Product Portfolio
Figure 14.20: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 14.21: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 14.22: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 14.23: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 14.24: QIAGEN N.V.: SWOT Analysis
Figure 14.25: Abbott Laboratories: Key Product Offerings
Figure 14.26: Abbott Laboratories: Overall Financials, 2017-2019
Figure 14.27: Abbott Laboratories: Revenue (by Segment), 2017-2019
Figure 14.28: Abbott Laboratories: Revenue Split for Diagnostics, 2017-2019
Figure 14.29: Abbott Laboratories: Revenue (by Region), 2017-2019
Figure 14.30: Abbott Laboratories: R&D Expenditure, 2017-2019
Figure 14.31: Abbott Laboratories: SWOT Analysis
Figure 14.32: Thermo Fisher Scientific Inc.: Key Product Offerings
Figure 14.33: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 14.34: Thermo Fisher Scientific Inc: Sales (by Segment), 2017-2019
Figure 14.35: Thermo Fisher Scientific Inc.: Sales (by Region), 2017-2019
Figure 14.36: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 14.37: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 14.38: Danaher Corporation: Product Portfolio
Figure 14.39: Danaher Corporation: Overall Financials, 2017-2019
Figure 14.40: Danaher Corporation: Revenue (by Business Segment), 2017-2019
Figure 14.41: Danaher Corporation: Revenue (by Region), 2017-2019
Figure 14.42: Danaher Corporation: R&D Expenditure, 2017-2019
Figure 14.43: Danaher Corporation: SWOT Analysis
Figure 14.44: Myriad Genetics, Inc.: Overall Product Portfolio
Figure 14.45: Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 14.46: Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019
Figure 14.47: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 14.48: Myriad Genetics, Inc.: SWOT Analysis
Figure 14.49: Laboratory Corporation of America Holdings: Overall Product Portfolio
Figure 14.50: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
Figure 14.51: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
Figure 14.52: Laboratory Corporation of America Holdings: Revenue (by Region), 2018
Figure 14.53: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 14.54: Siemens Healthineers, Inc.: Overall Product Portfolio
Figure 14.55: Siemens Healthineers, Inc.: Overall Financials, 2017-2019
Figure 14.56: Siemens Healthineers, Inc.: Revenue (by Segment), 2017-2019
Figure 14.57: Siemens Healthineers, Inc.: Revenue (by Region), 2017-2019
Figure 14.58: Siemens Healthineers, Inc.: R&D Expenditure, 2017-2019
Figure 14.59: Siemens Healthineers, Inc.: SWOT Analysis
Figure 14.60: Quest Diagnostics Incorporated: Overall Product Portfolio
Figure 14.61: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 14.62: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2017-2019
Figure 14.63: Quest Diagnostics Incorporated: SWOT Analysis
Figure 14.64: Bio-Rad Laboratories, Inc.: Key Product Portfolio
Figure 14.65: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
Figure 14.66: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 14.67: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
Figure 14.68: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 14.69: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 14.70: Sysmex Corporation: Overall Product Portfolio
Figure 14.71: Sysmex Corporation: Overall Financials, 2017-2019
Figure 14.72: Sysmex Corporation: Sales (by Segment), 2017-2019
Figure 14.73: Sysmex Corporation: Sales (by Region), 2017-2019
Figure 14.74: Sysmex Corporation: R&D Expenditure, 2017-2019
Figure 14.75: Sysmex Corporation: SWOT Analysis
Figure 14.76: bioMérieux S.A.: Overall Product Portfolio
Figure 14.77: bioMérieux S.A.: Overall Financials, 2017-2019
Figure 14.78: bioMérieux S.A.: Revenue (by Segment), 2017-2019
Figure 14.79: bioMérieux S.A.: Revenue (by Region), 2017-2019
Figure 14.80: bioMérieux S.A.: R&D Expenditure, 2017-2019
Figure 14.81: bioMérieux S.A.: SWOT Analysis
Figure 14.82: Beckton, Dickinson and Company: Overall Product Portfolio
Figure 14.83: Becton, Dickinson and Company: Overall Financials, 2017-2019
Figure 14.84: Becton, Dickinson and Company: Revenue (by Business Segment), 2017-2019
Figure 14.85: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
Figure 14.86: Becton, Dickinson and Company: R&D Expenditure, 2017-2019
Figure 14.87: Becton, Dickinson and Company: SWOT Analysis
Figure 14.88: Ortho Clinical Diagnostics: Overall Product Portfolio
Figure 14.89: Ortho Clinical Diagnostics: SWOT Analysis
Figure 14.90: Hologic, Inc.: Overall Product Portfolio
Figure 14.91: Hologic, Inc.: Overall Financials, 2017-2019
Figure 14.92: Hologic, Inc.: Revenue (by Segment), 2017-2019
Figure 14.93: Hologic, Inc.: Revenue (by Region), 2017-2019
Figure 14.94: Hologic, Inc.: R&D Expenditure, 2017-2019
Figure 14.95: Hologic, Inc.: SWOT Analysis
Figure 14.96: DiaSorin S.p.A.: Overall Product Portfolio
Figure 14.97: DiaSorin S.p.A.: Overall Financials, 2017-2019
Figure 14.98: DiaSorin S.p.A.: Revenue (by Segment), 2017-2019
Figure 14.99: DiaSorin S.p.A.: by Region, 2017-2019
Figure 14.100: DiaSorin S.p.A: R&D Expenditure, 2017-2019
Figure 14.101: DiaSorin S.p.A: SWOT Analysis
Figure 14.102: Transasia Bio-Medicals Ltd.: Overall Product Portfolio
Figure 14.103: Transasia Bio-Medicals Ltd.: SWOT Analysis